Teva Pharmaceutical Industries Ltd. $TEVA Shares Acquired by Signaturefd LLC

Signaturefd LLC lifted its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 45.0% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,814 shares of the company’s stock after acquiring an additional 3,046 shares during the period. Signaturefd LLC’s holdings in Teva Pharmaceutical Industries were worth $164,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in TEVA. Golden State Wealth Management LLC acquired a new stake in Teva Pharmaceutical Industries in the first quarter worth $39,000. New Age Alpha Advisors LLC acquired a new stake in Teva Pharmaceutical Industries in the first quarter worth $43,000. Compagnie Lombard Odier SCmA acquired a new stake in Teva Pharmaceutical Industries in the first quarter worth $54,000. Banque Cantonale Vaudoise acquired a new stake in Teva Pharmaceutical Industries in the first quarter worth $74,000. Finally, Brooklyn Investment Group increased its position in Teva Pharmaceutical Industries by 403.4% in the first quarter. Brooklyn Investment Group now owns 5,009 shares of the company’s stock worth $77,000 after buying an additional 4,014 shares during the period. 54.05% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Trading Down 0.2%

Shares of TEVA stock opened at $20.01 on Friday. The stock has a 50-day simple moving average of $18.12 and a 200 day simple moving average of $16.81. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $12.47 and a fifty-two week high of $22.80. The stock has a market capitalization of $22.94 billion, a P/E ratio of -125.03, a P/E/G ratio of 1.17 and a beta of 0.71. The company has a quick ratio of 0.77, a current ratio of 1.06 and a debt-to-equity ratio of 2.45.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.02. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The business had revenue of $4.18 billion during the quarter, compared to analysts’ expectations of $4.34 billion. During the same quarter last year, the business posted $0.61 earnings per share. The company’s quarterly revenue was up .3% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. On average, sell-side analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Eric A. Hughes sold 52,742 shares of the stock in a transaction on Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $799,568.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Placid Jover sold 6,053 shares of the stock in a transaction on Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $91,763.48. Following the completion of the transaction, the insider owned 6,774 shares of the company’s stock, valued at $102,693.84. This trade represents a 47.19% decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.49% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. UBS Group increased their target price on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a “buy” rating in a research report on Wednesday, September 24th. The Goldman Sachs Group assumed coverage on Teva Pharmaceutical Industries in a research note on Friday, June 6th. They issued a “buy” rating and a $24.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Saturday, September 27th. JPMorgan Chase & Co. increased their price target on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock an “overweight” rating in a research note on Friday. Finally, Wall Street Zen raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Saturday, July 26th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $25.57.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.